Study guide
7.2 Differentiating PEW, Sarcopenia & Cachexia in CKD
Board Certified Specialist in Renal Nutrition CSR
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & Kidney Disease Foundations
1.1 CDR CSR Exam Structure, Eligibility, Logistics & the 2023 Content Outline 1.2 Renal Anatomy, Physiology & Glomerular Hemodynamics 1.3 CKD Etiology, KDIGO Staging & Progression Risk
2 Chapter 2: Domain 1 — Anthropometric & Body Composition Assessment
2.1 Dry Weight Determination, Fluid Assessment & Interdialytic Weight Gain 2.2 Anthropometric Measurement Standards (Knee Height, Skinfolds, Frame Size) 2.3 Body Composition Analysis: BIA, BIS, DXA & Handgrip Dynamometry
3 Chapter 3: Domain 1 — Nutrition-Focused Physical Findings & PEW Assessment Tools
3.1 Protein-Energy Wasting (PEW) Diagnostic Criteria & Pathophysiology 3.2 Subjective Global Assessment (7-Point SGA) in Dialysis 3.3 Malnutrition Inflammation Score (MIS) & Scoring Protocols 3.4 Nutrition-Focused Physical Exam (NFPE) for Muscle & Fat Loss
4 Chapter 4: Domain 1 — Diet, Medical, Medication & Psychosocial History
4.1 Dietary Intake Assessment & Food Frequency Methods in CKD 4.2 Medical & Medication History: Drug–Nutrient Interactions and Supplements 4.3 Psychosocial, Social & Functional History in Renal Nutrition Assessment
5 Chapter 5: Domain 1 — Medical Tests & Procedures by Treatment Modality
5.1 Hemodialysis Clinical Assessment & Vascular Access Considerations 5.2 Peritoneal Dialysis & Peritoneal Glucose Absorption Assessment 5.3 AKI, CRRT & Pediatric Renal Disease Assessment
6 Chapter 6: Domain 1 — Nutrition Diagnosis: Terminology, Etiology & Reasoning
6.1 Standardized Nutrition Diagnostic Terminology (NCP) in Nephrology 6.2 Etiology & Root-Cause Analysis for Renal Nutrition Problems 6.3 Diagnostic Reasoning for Fluid, Mineral & Protein Imbalances
7 Chapter 7: Domain 1 — Nutrition Diagnosis in Complex Patients
7.1 Formulating Valid PES Statements in Complex Dialysis Patients 7.2 Differentiating PEW, Sarcopenia & Cachexia in CKD 7.3 Diagnostic Prioritization across Cardiorenal & Diabetic Nephropathy
8 Chapter 8: Domain 2 — Food & Nutrient Delivery: Protein & Energy
8.1 KDOQI 2020 Protein Targets: Non-Dialysis CKD (LPD vs. VLPD) 8.2 Protein Prescriptions for Hemodialysis and Peritoneal Dialysis 8.3 Energy Requirements, Carbohydrates & Plant-Dominant Diets (PLADO)
9 Chapter 9: Domain 2 — Electrolytes, Fluid, Acid–Base & Micronutrients
9.1 Potassium Management: Dietary Restriction, Leaching & K-Binders 9.2 Sodium & Fluid Prescriptions across Dialysis Modalities 9.3 Acid-Base Homeostasis & Bicarbonate Replacement Therapy 9.4 Micronutrient, Trace Mineral & Vitamin Supplementation in ESRD
10 Chapter 10: Domain 2 — Medications & Specialized Nutrition Support
10.1 CKD-MBD Pharmacology: Phosphorus Binders, Vitamin D & Calcimimetics 10.2 Anemia Management: Iron Homeostasis, IV Iron Protocols & ESAs 10.3 Enteral, IDPN & Intraperitoneal Amino Acid Nutrition Support
11 Chapter 11: Domain 2 — Treatments Across the Continuum: Transplant & Comorbidities
11.1 Kidney Transplant I: Candidacy, Living Donors & the Early Post-Transplant Period 11.2 Kidney Transplant II: Long-Term Care, Immunosuppressant Side Effects & Graft Protection 11.3 Diabetes Management Across CKD Stages: Glycemic Targets, Medications & MNT 11.4 GI & Cardiovascular Comorbidities: Gastroparesis, Constipation, Liver Disease, Lipids & Blood Pressure
12 Chapter 12: Domain 2 — Monitoring & Evaluation: Labs, Fluid & Nutrition Trends
12.1 Renal Laboratory Surveillance: Frequency, Target Ranges & Trending 12.2 Monitoring Fluid Balance, Blood Pressure & Cardiovascular Risk 12.3 Longitudinal Assessment of Nutritional Status & Weight Trajectories
13 Chapter 13: Domain 2 — Monitoring Dialysis Adequacy & Kinetics
13.1 Hemodialysis Adequacy: Urea Kinetic Modeling, spKt/V & URR 13.2 Peritoneal Dialysis Adequacy & Peritoneal Equilibration Test (PET) 13.3 Normalized Protein Catabolic Rate (nPCR / nPNA) Interpretation 13.4 Troubleshooting Inadequate Dialysis vs. Dietary Non-Adherence
14 Chapter 14: Domain 2 — Care Coordination, Communication & Education
14.1 Interdisciplinary Team Care, Patient Education & Counseling Ethics 14.2 Individualized & Group Education: Medicare MNT and KDE Benefits, Caregivers & Curricula 14.3 Interfacility Coordination of Care: Hospital Handoffs, Transfers, Transplant Centers & Modality Changes 14.4 Psychosocial Support & Resources: Food Assistance, Financial Programs, Rehabilitation & Peer Support
15 Chapter 15: Domain 3 — Regulations & Quality Management
15.1 CMS Conditions for Coverage: IDT, Dietitian Qualifications, Assessment & Plan-of-Care Timelines 15.2 QAPI Programs, PDSA Cycles & the ESRD Quality Incentive Program 15.3 Medicare ESRD Payment, ESRD Networks, EQRS & the Survey Measures Assessment Tool
16 Chapter 16: Domain 3 — Evidence-Based Practice: Guidelines, Research & Protocols
16.1 The KDOQI 2020 Nutrition in CKD Guideline (NKF–Academy EAL): Grades & Key Statements 16.2 KDIGO & Companion Guidelines: CKD 2024, CKD-MBD, Anemia 2026, Diabetes, BP, Lipids & AKI 16.3 Appraising Current Research: Study Designs, Bias, Statistics & Landmark Renal Trials 16.4 Clinical Protocols & Algorithms: Dietitian-Managed MBD, Anemia, Potassium & Nutrition-Support Pathways
7.2 Differentiating PEW, Sarcopenia & Cachexia in CKD
Key Takeaways Explain This Topic AI
Protein-Energy Wasting (PEW) is a uremia-specific wasting syndrome diagnosed via the ISRNM consensus criteria requiring at least one objective abnormality across three of four categories: serum chemistry, body mass, muscle mass, and dietary intake.
Sarcopenia in CKD is defined by the EWGSOP2 framework: initiated by low muscle strength (handgrip dynamometry <27 kg for men, <16 kg for women), confirmed by low muscle quantity/quality (DXA ASMM <20 kg for men, <15 kg for women), and staged as severe when physical performance is impaired (gait speed ≤0.8 m/s).
Sarcopenic obesity represents the highest mortality risk phenotype in end-stage renal disease, where excess adipose tissue masks severe skeletal muscle wasting and secretes pro-inflammatory adipokines that exacerbate vascular calcification.
Cachexia is a severe metabolic syndrome driven by intense systemic inflammation (hs-CRP >10 mg/L, TNF-α, IL-6) and profound hypercatabolism that remains largely refractory to standard caloric supplementation alone without mitigating underlying inflammatory drivers.
Simple starvation is characterized by pure nutrient deprivation in the absence of systemic inflammation (normal hs-CRP <3.0 mg/L), adaptive downregulation of resting energy expenditure, preserved visceral proteins until late stages, and rapid reversal upon refeeding.
Last updated: September 2026
Differentiating PEW, Sarcopenia & Cachexia in CKD
Core Clinical Principle: Not all weight loss and muscle depletion in chronic kidney disease stem from the same biological mechanism. Prescribing isolated hypercaloric oral supplements to a patient with cytokine-driven cachexia or uremic PEW fails to halt muscle proteolysis unless systemic inflammation, uremic toxicity, and metabolic acidosis are concurrently resolved. In contrast, simple starvation responds immediately to caloric repletion. Accurate differential diagnosis is essential for effective clinical management.
Patients with Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD) suffer from an extraordinary prevalence of somatic wasting, functional disability, and frailty. Historically, terms such as "renal malnutrition," "uremic cachexia," and "sarcopenia" were used interchangeably, creating diagnostic confusion and ineffective clinical trials. Today, distinct international consensus definitions establish clear boundaries between four primary wasting conditions: Protein-Energy Wasting (PEW) , Sarcopenia , Disease-Related Cachexia , and Simple Starvation .
1. Protein-Energy Wasting (PEW) in CKD
Formally defined in 2008 by the International Society of Renal Nutrition and Metabolism (ISRNM) , PEW refers to the state of decreased body stores of protein and energy fuels (somatic muscle and adipose compartments) alongside depleted visceral proteins, specifically induced by kidney disease and uremic toxicity.
The ISRNM Diagnostic Criteria
To establish a confirmed diagnosis of PEW, a patient must satisfy at least one objective criterion across at least three of the four diagnostic categories : ┌────────────────────────────────────────────────────────────────────────┐
- │ ISRNM PEW Diagnostic Framework │
- │ (Requires ≥ 1 criterion in ≥ 3 of the 4 categories) │
- ├────────────────────────────────────────────────────────────────────────┤
- │ 1. Serum Chemistry: │
- │ • Serum Albumin < 3.8 g/dL (bromocresol green method) │
- │ • Serum Prealbumin < 30 mg/dL (maintenance dialysis) │
- │ • Serum Total Cholesterol < 100 mg/dL (unintentional hypochol.) │
- │ │
- │ 2. Body Mass: │
- │ • BMI < 23 kg/m² │
- │ • Unintentional weight loss > 5% over 3 mo OR > 10% over 6 mo │
- │ • Total Body Fat < 10% │
- │ │
- │ 3. Muscle Mass: │
- │ • Skeletal muscle mass loss > 5% over 3 mo OR > 10% over 6 mo │
- │ • Mid-Arm Muscle Circumference (MAMC) reduction > 10% vs median │
- │ │
- │ 4. Dietary Intake: │
- │ • Low protein intake < 0.8 g/kg/d on dialysis (< 0.6 in CKD 2–5) │
- │ • Low energy intake: < 25 kcal/kg/d for ≥ 2 continuous months │
- └────────────────────────────────────────────────────────────────────────┘
- Pathophysiological Hallmarks
PEW is driven by accelerated myofibrillar protein degradation through the ATP-dependent 26S ubiquitin-proteasome system (UPS) , triggered by caspase-3 cleavage of actomyosin , metabolic acidosis (serum HCO 3 − < 22 \text{HCO}_3^- < 22 HCO 3 − < 22 mEq/L), gut-derived uremic toxins (indoxyl sulfate, p-cresyl sulfate), insulin resistance, and obligatory dialytic nutrient clearance (6–12 g free amino acids lost per HD treatment; 5–15 g protein lost daily in PD effluent).
2. Sarcopenia in Kidney Disease
Sarcopenia is a progressive and generalized skeletal muscle disorder involving the accelerated loss of muscle mass and muscle function. In nephrology, sarcopenia is accelerated by uremic myopathy, physical inactivity, mitochondrial decay, and motor unit denervation.
EWGSOP2 Consensus Staging Framework
The European Working Group on Sarcopenia in Older People 2 (EWGSOP2) framework utilizes a three-tiered diagnostic staging sequence:
Sarcopenia Stage Mandatory Diagnostic Parameter Objective Measurement Method & Cutoff
1. Probable Sarcopenia Low Muscle Strength (Primary indicator) • Handgrip Dynamometry: < 27 kg in men; < 16 kg in women; Chair Stand Test: > 15 seconds for 5 consecutive rises
2. Confirmed Sarcopenia Low Muscle Quantity / Quality (Confirms diagnosis) • Appendicular Skeletal Muscle Mass (ASMM) via DXA: < 20 kg in men; < 15 kg in women; ASMM / Height² (ASMMI): < 7.0 kg/m² in men; < 5.5 kg/m² in women; BIA-derived SMI (Asian Working Group for Sarcopenia 2019 cutoffs): < 7.0 kg/m² (men); < 5.7 kg/m² (women)
3. Severe Sarcopenia Impaired Physical Performance (Determines severity) • Usual Gait Speed: ≤ 0.8 m/s over 4-meter course; Short Physical Performance Battery (SPPB): ≤ 8 points ; Timed Up and Go (TUG): ≥ 20 seconds
Sarcopenic Obesity: The Lethal Phenotype
In maintenance dialysis, an elevated Body Mass Index (BMI ≥ 25 – 34.9 \ge 25\text{--}34.9 ≥ 25 – 34.9 kg/m²) is epidemiologically associated with improved survival—a phenomenon known as the obesity paradox or reverse epidemiology. However, sarcopenic obesity represents a critical clinical exception and the most dangerous body composition phenotype in nephrology.
Definition: The coexistence of excess body fat (BMI ≥ 30 \ge 30 ≥ 30 kg/m², or body fat percentage > 25 % >25\% > 25% in men, > 35 % >35\% > 35% in women) with severe skeletal muscle depletion (low ASMMI) and functional weakness.
Mechanism: Excess adipose tissue actively secretes pro-inflammatory cytokines (IL-6, TNF-α, leptin, resistin) and non-esterified fatty acids that infiltrate remaining skeletal myocytes ( myosteatosis ). Intramyocellular lipid accumulation impairs mitochondrial beta-oxidation and drives severe insulin resistance.
Mortality Risk: Dialysis registry studies demonstrate that patients with sarcopenic obesity experience the highest cardiovascular and all-cause mortality rates of any subgroup, far exceeding patients with normal body composition or isolated non-sarcopenic obesity.
3. Disease-Related Cachexia
Cachexia is a complex metabolic syndrome associated with underlying chronic illness (such as ESRD, advanced congestive heart failure, cancer, or severe chronic obstructive pulmonary disease) characterized by an extreme loss of muscle with or without loss of fat mass.
Consensus Criteria (Evans et al.)
A formal diagnosis of cachexia requires unintentional non-edematous weight loss ≥ 5 % \ge 5\% ≥ 5% over 12 months (or BMI < 20 <20 < 20 kg/m² in the presence of chronic illness) PLUS at least three of the following five clinical criteria :
Decreased Muscle Strength: Handgrip strength in the lowest tertile.
Fatigue / Exhaustion: Inability to perform customary physical activities.
Anorexia: Markedly reduced food intake ( < 20 <20 < 20 kcal/kg/day or < 70 % <70\% < 70% of normal energy intake).
Low Fat-Free Mass Index: Lean tissue depletion confirmed by DXA or skinfold anthropometry.
Abnormal Biochemistry: Evidence of active systemic inflammation ( hs-CRP > 5.0 >5.0 > 5.0 mg/L ), anemia ( hemoglobin < 12.0 <12.0 < 12.0 g/dL ), or visceral hypoalbuminemia ( serum albumin < 3.2 <3.2 < 3.2 g/dL ).
Cachexia vs. PEW: The Distinguishing Line
While PEW is specific to the uremic milieu of kidney disease and incorporates dialytic protein clearance and kidney-specific thresholds (e.g., nPCR < 0.8 <0.8 < 0.8 g/kg/d, BMI < 23 <23 < 23 ), cachexia represents the terminal hyper-inflammatory, hypercatabolic end-stage of chronic disease . Patients with cachexia exhibit marked, persistent elevations in inflammatory cytokines (hs-CRP frequently > 10 – 20 >10\text{--}20 > 10 – 20 mg/L, elevated circulating TNF-α), hypermetabolism, accelerated lipolysis, and severe neuroendocrine appetite failure mediated by central melanocortin activation.
4. Simple Starvation (Pure Malnutrition)
Simple starvation refers to involuntary or voluntary pure caloric and/or protein deprivation occurring in the absence of underlying systemic inflammation or hypercatabolism (e.g., food insecurity, mechanical dysphagia, isolated psychiatric anorexia).
Adaptive Metabolic Response
The human body possesses powerful neuroendocrine adaptations to simple starvation designed to prolong survival:
Suppression of Resting Energy Expenditure (REE): REE decreases by 15–30% through down-regulation of thyroid hormone conversion (triiodothyronine [T3] to reverse T3) and sympathetic nervous system tone.
Selective Adipose Mobilization: Lipolysis is upregulated to supply free fatty acids and ketone bodies (acetoacetate, beta-hydroxybutyrate) as fuel for the central nervous system, drastically sparing skeletal muscle protein breakdown.
Conservation of Visceral Protein Synthesis: In simple starvation without inflammation, hepatic synthesis of albumin, prealbumin, and transferrin remains intact until terminal exhaustion. Therefore, serum albumin is often completely normal (e.g., 4.0–4.2 g/dL) in early-to-moderate starvation.
Responsiveness to Feeding: Simple starvation is fully and rapidly reversible upon providing adequate dietary energy and protein, exhibiting none of the metabolic resistance seen in PEW or cachexia.
5. Master Differential Diagnosis Matrix
The following clinical matrix synthesizes the pathophysiological, biochemical, and functional distinctions essential for the CSR examination:
Diagnostic Parameter Simple Starvation Sarcopenia Protein-Energy Wasting (PEW) Disease-Related Cachexia
Primary Underlying Driver Absolute nutrient deficit / food deprivation Aging, uremic myopathy, neuromuscular disuse Uremic toxicity, dialytic losses, acidosis, mild inflammation Intense systemic inflammation, severe chronic disease
Inflammatory State (hs-CRP) Normal (< 3.0 mg/L) Normal to minimally elevated (< 5.0 mg/L) Mild-to-moderate elevation (3.0–10.0 mg/L) Markedly elevated (> 10.0 mg/L, often > 20 mg/L)
Somatic Skeletal Muscle Spared initially; lost in late-stage deprivation Severely depleted (Low ASMM, low grip strength) Progressively depleted (UPS actomyosin proteolysis) Profoundly depleted (Massive cytokine-driven proteolysis)
Adipose Stores (Fat Mass) Severely and rapidly depleted (Primary fuel) Often preserved or excessive (Sarcopenic obesity) Progressively depleted (ISRNM: fat < 10%) Severely depleted (Marked cytokine-driven lipolysis)
Visceral Proteins (Albumin) Normal until terminal stage (> 3.8 g/dL) Normal (Unless comorbid PEW/inflammation present) Sub-target (< 3.8 g/dL by BCG) Severely suppressed (< 3.2 g/dL)
Resting Energy Expenditure Decreased (-15% to -30% metabolic adaptation) Normal for age and lean body mass Normal to elevated (Uncoupled oxidative phosphorylation) Markedly elevated (Hypermetabolism)
Physical Performance Preserved until late stage Severely impaired (Gait speed ≤ 0.8 m/s, SPPB ≤ 8) Mild-to-moderately impaired Profoundly impaired (Severe bedridden fatigue)
Response to Nutrition Alone Prompt, complete reversal with feeding Minimal to modest (Requires targeted resistance training) Partial / slow (Requires resolving uremia, acidosis, adequacy) Refractory (Requires resolving underlying inflammatory driver)
Consensus Diagnostic System Standard Clinical Malnutrition (AND/ASPEN) EWGSOP2 Criteria (Strength → \rightarrow → Mass → \rightarrow → Performance) ISRNM Criteria ( ≥ 1 \ge 1 ≥ 1 sign in ≥ 3 \ge 3 ≥ 3 of 4 categories) Evans et al. Consensus Criteria